Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin November 12, 2020 Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress Read More »
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results Portfolio News / By Karina Tin November 12, 2020 NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results Read More »
eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Portfolio News / By Karina Tin November 12, 2020 eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Read More »
ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update Portfolio News / By Karina Tin November 5, 2020 ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update Read More »
Surrozen Appoints Charles Williams as Chief Financial Officer Portfolio News / By Karina Tin October 30, 2020 Surrozen Appoints Charles Williams as Chief Financial Officer Read More »
Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results Portfolio News / By Karina Tin October 29, 2020 Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results Read More »
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers Portfolio News / By Karina Tin October 24, 2020 Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers Read More »
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4 Portfolio News / By Karina Tin October 19, 2020 NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4 Read More »
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program Portfolio News / By Karina Tin October 19, 2020 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program Read More »
eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer Portfolio News / By Karina Tin October 15, 2020 eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer Read More »
